Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. September 2025 02:00 ET | Quelle: Citryll

FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA TRIAL EVALUATING CIT-013 IN RHEUMATOID ARTHRITIS

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis Oss, Netherlands – 2 September 2025 –...
09. Dezember 2024 02:00 ET | Quelle: Citryll

Citryll Raises EUR 85 Million Series B to Advance Novel NET-Targeting Therapy for Immune-Mediated Inflammatory Disorders

CITRYLL RAISES EUR 85 MILLION SERIES B TO ADVANCE NOVEL NET-TARGETING THERAPY FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS Financing co-led by Johnson & Johnson Innovation – JJDC, Inc., Forbion and...
03. Oktober 2024 02:00 ET | Quelle: Citryll

Citryll and leading rheumatology centres receive Reumanederland grant to collaborate on NET research to advance novel treatments for rheumatoid arthritis.

CITRYLL AND LEADING RHEUMATOLOGY CENTRES RECEIVE REUMANEDERLAND GRANT TO COLLABORATE ON NET RESEARCH TO ADVANCE NOVEL TREATMENTS FOR RHEUMATOID ARTHRITIS Learnings will be used in the clinical...
31. Juli 2024 02:00 ET | Quelle: Citryll

CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013

CITRYLL COMPLETES PATIENT DOSING IN THE REPEAT DOSE STAGE OF THE PHASE 1 TRIAL FOR THE NOVEL ANTI-INFLAMMATORY CANDIDATE CIT-013 Oss, Netherlands – 31 July 2024 – Citryll, a clinical-stage biotech...